|1.||Llevadot, J: 4 articles (11/2001 - 11/2000)|
|2.||Giugliano, R P: 3 articles (11/2001 - 07/2001)|
|3.||Antman, E M: 3 articles (11/2001 - 07/2001)|
|4.||Schröder, K: 2 articles (11/2001 - 08/2001)|
|5.||Tebbe, U: 2 articles (11/2001 - 11/2001)|
|6.||Schröder, R: 2 articles (11/2001 - 08/2001)|
|7.||Wegscheider, K: 2 articles (11/2001 - 08/2001)|
|8.||Zeymer, U: 2 articles (11/2001 - 08/2001)|
|9.||Gurfinkel, E P: 2 articles (11/2001 - 09/2001)|
|10.||Braunwald, E: 2 articles (11/2001 - 09/2001)|
11/01/2000 - "Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction."
01/01/2002 - "Lanoteplase plasma clearance averaged 3 L/h (50 ml/min), whereas the mean plasma clearance of approximately 24 L/h (400 ml/min) for alteplase approaches hepatic blood flow following acute myocardial infarction. "
11/03/2001 - "An ST-segment resolution substudy was done in conjunction with the Intravenous nPA for Treatment of Infarcting Myocardium Early (InTIME) II Study, which compared mortality in patients with acute myocardial infarction randomly assigned lanoteplase or alteplase. "
09/01/2001 - "We examined the geographic variations in InTIME-II, a randomized double-blind trial comparing alteplase with lanoteplase for myocardial infarction. "
08/01/2001 - "In conjunction with the Intravenous nPA for Treatment of Infarcting Myocardium Early (InTIME) II Study, which compared mortality in patients with acute myocardial infarction randomized within 6 hours of symptom onset to receive either Lanoteplase or Alteplase, all 3593 German and Polish patients participated in an ST segment resolution substudy. "
|2.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
02/24/1995 - "SUN9216 (1 mg/kg) was injected intravenously 30 min after the middle cerebral artery occlusion and the time for reopening of the middle cerebral artery by SUN9216 was monitored for a 60-min period under an operating microscope. "
07/01/1993 - "The reopening of the middle cerebral artery by SUN9216, injected 30 minutes after middle cerebral artery occlusion, was observed under an operation microscope for a 60-minute observation period. "
09/01/1994 - "Thrombolytic efficacy of a modified tissue-type plasminogen activator, SUN9216, in the rat middle cerebral artery thrombosis model."
09/01/1994 - "Further, the area of ischaemic cerebral damage caused by the middle cerebral artery occlusion was significantly (P < 0.05) reduced by SUN9216, but in this respect, recombinant tissue-type plasminogen activator was ineffective."
07/01/1993 - "We aimed to evaluate a modified tissue-type plasminogen activator, SUN9216, and the combination of SUN9216 and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. "
|3.||Intracranial Hemorrhages (Intracranial Hemorrhage)
07/25/2001 - "Lanoteplase and heparin bolus plus infusion is as effective as tPA with regard to mortality, but the rate of intracranial hemorrhage is significantly higher. "
05/01/2014 - "Recombinant PAs or rt-PAs like alteplase, retelase, saruplase, tenecteplase, lanoteplase, and desmoteplase became available in the drug markets with advantages of less binding loci with PAI-1 to avoid degradation while providing faster and more complete reperfusion in a greater number of patients with less risk of bleeding and intracranial hemorrhage. "
02/24/1995 - "In the rats in which thrombolysis was achieved with SUN9216, the size of the cerebral infarction was significantly (P < 0.05) reduced as compared with that in the rats treated with saline and was comparable to the reduction produced by the combination doses. "
07/01/1993 - "The area of cerebral infarction in rats reperfused with SUN9216 was significantly reduced compared with that in the control group. "
07/01/1993 - "A single injection of SUN9216 was effective in recanalizing the vessel and reducing the area of cerebral infarction."
02/24/1995 - "We were interested to investigate if a combination of a modified tissue-type plasminogen activator, SUN9216, which is constructed by modifying a single amino acid (Asn117-Gln117) to yield a tissue-type plasminogen activator lacking finger and growth factor domains with a long half-life in blood, and an endothelin receptor antagonist, FR139317, (R)2-[(R)-2-[(S)-2[[1-(hexahydro-1H-azepinyl)]carbonyl]amino-4- methyl-pentanoyl]amino-3-[3-(1-methyl-1H-indolyl)]propionyl)amino-3- (2-pyridyl)propionic acid, has greater thrombolytic efficacy than a thrombolytic agent alone in reducing the size of cerebral infarction. "
12/01/2000 - "Total stroke occurred in 1.53% alteplase- and 1.87% lanoteplase-treated patients (ns); haemorrhagic stroke rates were 0.64% alteplase and 1.12% lanoteplase (P=0.004). "
03/01/2000 - "From preliminary results of the large InTIME-II study, lanoteplase 120 kU/kg showed a greater incidence of intracranial haemorrhage and mild bleeding than alteplase <or=100mg, but a similar incidence of stroke. "
01/01/2003 - "Third-generation agents, such as reteplase, lanoteplase and tenecteplase, offer superior recanalisation rates with limited systemic adverse effects and might prove to be the agents of choice for intra-arterial acute stroke thrombolysis in the future. "
|1.||Tissue Plasminogen Activator (Alteplase)
|3.||glucuronyl glucosamine glycan sulfate (Vessel)
|6.||Plasminogen Activators (Plasminogen Activator)
|7.||Fibrinolytic Agents (Antithrombotic Agents)
|10.||S- (2- chloro- 1,1,2- trifluoroethyl)cysteine (CTFC)